Part 1: Foundational Biochemistry & Cell Biology

This section covers the fundamental chemical building blocks and processes that are essential for understanding neurotransmitter function, receptor synthesis, and drug action. While not the primary focus of clinical psychiatry, a firm grasp of these basics is crucial for the MRCPsych exam.

1.1. Basic Building Blocks

Neurochemistry is built upon the interaction of specific organic molecules. Understanding their basic nature is important.

• Purines: These are a class of nitrogen-containing aromatic heterocyclic compounds. In neurochemistry, they are vital for two main reasons:
  1. Components of Nucleic Acids: Adenine (A) and Guanine (G) are the two purine bases that form the building blocks of DNA and RNA. This is the foundation for the genetic code that dictates the synthesis of all proteins in the neuron, including receptors, transporters, and enzymes.
  2. Signaling and Energy: Adenosine Triphosphate (ATP) is not only the primary energy currency for cellular processes (like ion pumps and neurotransmitter transport) but also acts as a neurotransmitter itself, signaling through purinergic receptors. Guanine Triphosphate (GTP) is essential for the function of G-protein coupled receptors (GPCRs).
• DNA Methylation: This is the most common and fundamental epigenetic mechanism.
  • The Chemical Process: It involves the addition of a methyl group (-CH₃) to a DNA molecule. This modification does not change the underlying DNA sequence.
  • The Specific Site: In vertebrates, this process almost exclusively occurs at the 5th carbon position of the cytosine base, particularly when it is followed by a guanine base (a "CpG dinucleotide"). This chemical modification is carried out by enzymes called DNA methyltransferases.
  • The Neurochemical Consequence: Methylation typically acts to silence or repress gene transcription. By controlling which genes are "on" or "off," it powerfully regulates the synthesis of crucial neurochemical machinery, including neurotransmitter receptors, synthetic enzymes (e.g., GAD, Tyrosine Hydroxylase), and transporter proteins. Environmental factors can influence methylation patterns, providing a chemical link between experience and long-term changes in neuronal function.
  • Non-Epigenetic Modifications: It is important to distinguish this from processes like glycation, which is the non-enzymatic, haphazard attachment of sugar molecules to proteins or lipids and is not a regulated mechanism for gene control.

1.2. Important Metabolic Pathways & Enzyme Function

Enzymes are biological catalysts that facilitate virtually every chemical reaction in the neuron, from energy production to neurotransmitter synthesis and degradation. Understanding their roles is fundamental to neurochemistry and psychopharmacology.

1.2.1. The Krebs (TCA) Cycle and Neuropsychiatric Relevance

The Krebs cycle (or Tricarboxylic Acid Cycle) is a core metabolic pathway occurring in the mitochondria. Its primary function is to generate ATP, the energy currency essential for all neuronal functions, including maintaining ion gradients (Na+/K+ pump) and neurotransmitter transport.

• Thiamine (Vitamin B1) as a Co-factor: Several enzymes in this pathway require thiamine to function correctly.
• Clinical Relevance (Wernicke-Korsakoff Syndrome): In chronic alcoholism, thiamine deficiency is common. This impairs the function of thiamine-dependent enzymes, most notably α-ketoglutarate dehydrogenase. The resulting energy deficit disproportionately affects metabolically active and vulnerable brain regions like the mammillary bodies and thalamus, leading to the cell death and lesions that produce the amnesia and confabulation characteristic of Korsakoff's syndrome.

1.2.2. Alcohol Metabolism

The breakdown of ethanol is a two-step enzymatic process:

1. Ethanol → Acetaldehyde: Catalyzed by Alcohol Dehydrogenase (ADH). This is the rate-limiting step, meaning the overall speed of alcohol clearance is determined by the activity of this enzyme. Neonates have minimal ADH activity, making them highly vulnerable to alcohol toxicity.
2. Acetaldehyde → Acetate: Catalyzed by Aldehyde Dehydrogenase (ALDH).

• Pharmacological Relevance (Disulfiram): Disulfiram works by irreversibly inhibiting ALDH. If a person taking disulfiram consumes alcohol, the toxic metabolite acetaldehyde cannot be broken down. Its accumulation causes the highly unpleasant aversive reaction (flushing, nausea, tachycardia), which is the basis of its therapeutic use.

1.2.3. Enzyme Kinetics and Efficiency

• Diffusion-Limited Enzymes: Some enzymes are so efficient that their catalytic speed is limited only by the rate at which the substrate can physically diffuse into the active site.
• Acetylcholinesterase (AChE): This is the classic neurochemical example. It degrades acetylcholine in the synaptic cleft almost instantaneously (<1 millisecond). This extreme efficiency is crucial for the rapid, high-fidelity transmission required at the neuromuscular junction and in cholinergic pathways mediating attention.

1.2.4. Inherited Enzyme Deficiencies

• Lesch-Nyhan Syndrome: This is a rare X-linked recessive disorder caused by a deficiency of the enzyme hypoxanthine-guanine phosphoribosyltransferase (HGPRT). This enzyme is part of the purine salvage pathway. Its deficiency leads to a massive overproduction and accumulation of uric acid, resulting in severe neurological symptoms including dystonia, cognitive impairment, and characteristic self-mutilating behaviors (e.g., biting lips and fingers).

1.2.5. Important Enzymes in Neurotransmitter Synthesis & Degradation

These enzymes are central to neurochemistry and will be discussed in detail in later sections, but key examples include:

• Synthesis (Rate-Limiting): Tyrosine Hydroxylase is the rate-limiting enzyme for the synthesis of all catecholamines (dopamine, noradrenaline, adrenaline).
• Synthesis: Glutamate Decarboxylase (GAD) converts the excitatory neurotransmitter glutamate into the primary inhibitory neurotransmitter, GABA.
• Degradation: Monoamine Oxidase B (MAO-B) is the primary enzyme for degrading dopamine within the presynaptic terminal.

1.3. Cellular Death Mechanisms

The life and death of neurons are tightly regulated processes. Dysregulation of these pathways is central to neurodevelopmental disorders, acute brain injury, and chronic neurodegeneration. From a neurochemical perspective, the key distinction is between programmed, non-inflammatory death and unregulated, inflammatory death.

• Apoptosis (Programmed Cell Death): This is an orderly, energy-dependent process of cellular self-destruction. It is a "clean" or "tidy" process that avoids triggering inflammation.
  • Key Features: Cell shrinkage, Condensation of chromatin (pyknosis), Membrane "blebbing" (the membrane bulges outwards), Formation of apoptotic bodies which are then cleared by phagocytic cells (like microglia) without spilling their contents.
  • Neurochemical Relevance: Apoptosis is essential for normal brain development, including the pruning of excess neurons and synapses. It is also implicated in the slow, progressive neuronal loss seen in some neurodegenerative diseases. Crucially, it is non-inflammatory.
• Necrosis (Unregulated Cell Death): This is a "messy" and chaotic form of cell death that occurs in response to acute injury, such as trauma, ischemia (stroke), or toxins.
  • Key Features: Cellular swelling (oncosis), Loss of membrane integrity and rupture (lysis), Release of intracellular contents (e.g., enzymes, ions) into the extracellular space.
  • Neurochemical Relevance: The spillage of cellular contents acts as a damage signal that triggers a robust inflammatory response, involving the release of pro-inflammatory cytokines from surrounding glial cells. This inflammation can cause secondary damage to neighbouring, otherwise healthy neurons. Excitotoxicity, a process where excessive glutamate leads to cell death, often results in necrosis.

1.4. Precursor Molecules & Biosynthesis

Neurotransmitters are not created from scratch; they are synthesized from precursor molecules through specific enzymatic pathways. The availability of these precursors can be a rate-limiting factor in neurotransmitter production.

1.4.1. The Tryptophan Pathway: Serotonin and Melatonin

• The Precursor: The synthesis of serotonin begins with L-tryptophan, an essential amino acid that must be obtained from the diet. Its transport across the blood-brain barrier is a critical, rate-limiting step.
• The Pathway:
  1. Tryptophan is converted to 5-Hydroxytryptophan (5-HTP) by the enzyme tryptophan hydroxylase.
  2. 5-HTP is then converted to Serotonin (5-HT) by the enzyme aromatic L-amino acid decarboxylase.
• Serotonin as a Precursor: Serotonin itself serves as the direct precursor for the synthesis of melatonin, the hormone crucial for regulating circadian rhythms and sleep-wake cycles. This synthesis occurs primarily in the pineal gland.

1.4.2. The Tyrosine Pathway: The Catecholamines

• The Precursor: The synthesis of all catecholamines (dopamine, noradrenaline, and adrenaline) begins with the amino acid L-tyrosine.
• The Pathway:
  1. L-tyrosine undergoes hydroxylation to become L-DOPA. This step is catalyzed by the enzyme tyrosine hydroxylase, which is the rate-limiting enzyme for the entire catecholamine pathway.
  2. L-DOPA is then converted to Dopamine by the enzyme aromatic L-amino acid decarboxylase (sometimes called DOPA decarboxylase).
  3. Dopamine can then be further converted to noradrenaline, which can in turn be converted to adrenaline in relevant neurons.

1.4.3. Precursor Peptides: Pro-opiomelanocortin (POMC)

• The Concept: Unlike small-molecule neurotransmitters, many neuropeptides are synthesized as large, inactive precursor proteins called pro-peptides or pro-hormones. These are then cleaved by enzymes into smaller, biologically active peptides.
• POMC: Pro-opiomelanocortin is the classic example of a pro-peptide. It is a large protein that is processed to yield several crucial neuroactive molecules, including:
  • Adrenocorticotropic hormone (ACTH): Acts on the adrenal glands to stimulate the release of cortisol.
  • α-Melanocyte-stimulating hormone (α-MSH): Involved in appetite regulation.
  • β-endorphin: An endogenous opioid peptide involved in pain relief and reward.
• Important Distinction: POMC is NOT a precursor for other opioid peptides like enkephalins or other neuropeptides like Substance P.

Part 3: Receptor Families and Signal Transduction

Receptors are the protein targets for neurotransmitters and most psychotropic drugs. They are responsible for translating an extracellular chemical signal into an intracellular physiological response. They are broadly classified into three main families based on their structure and mechanism of action.

3.1. Ionotropic Receptors (Ligand-Gated Ion Channels)

These receptors mediate fast, direct synaptic transmission.

• Mechanism: The receptor itself is an ion channel. When a neurotransmitter (ligand) binds directly to the receptor, it causes an immediate conformational change, opening a pore in the center of the protein. This allows specific ions to flow across the cell membrane, rapidly changing the postsynaptic neuron's electrical potential.
• Analogy: A simple, spring-loaded gate. The neurotransmitter is the hand that pushes the gate open, allowing immediate passage.
• Structure: They are complex proteins made of multiple subunits (typically four or five) arranged around a central pore. Each individual subunit is a protein chain that typically spans the cell membrane four times.
• Speed: Very fast (milliseconds).

3.2. Metabotropic Receptors (G-Protein Coupled Receptors - GPCRs)

These receptors mediate slower, indirect, and modulatory effects. The vast majority of neurotransmitter receptors fall into this category.

• Mechanism: The receptor is not an ion channel itself. Instead, it is coupled to an intracellular protein called a G-protein. When a neurotransmitter binds, the receptor activates the G-protein, which then initiates a cascade of intracellular events, often involving second messengers.
• Analogy: A doorbell. The neurotransmitter is the finger that presses the button (receptor). This sends an electrical signal (G-protein) inside the house, which then rings a bell (second messenger), alerting the occupants to act.
• Structure: GPCRs consist of a single long polypeptide chain that snakes across the cell membrane seven times. This is often called a "7-transmembrane" or "serpentine" structure.
• Speed: Slower (seconds to minutes) but effects can be more widespread and longer-lasting.

3.3. Intracellular Second Messenger Systems

Second messengers are small intracellular molecules that are rapidly generated or mobilized in response to GPCR activation. They amplify and broadcast the initial signal throughout the neuron.

• The cAMP Pathway:
  • Activated by Gs (stimulatory) or Gi (inhibitory) G-proteins.
  • Gs stimulates the enzyme adenylyl cyclase, which converts ATP to cyclic AMP (cAMP).
  • Gi inhibits adenylyl cyclase, reducing cAMP levels.
  • cAMP goes on to activate other enzymes, like Protein Kinase A (PKA).
• The Phospholipase C (IP₃/DAG) Pathway:
  • Activated by Gq G-proteins.
  • Gq stimulates the enzyme phospholipase C (PLC).
  • PLC cleaves a membrane lipid (PIP₂) into two second messengers:
    1. Inositol Triphosphate (IP₃): Mobilizes Ca²⁺ from intracellular stores.
    2. Diacylglycerol (DAG): Activates Protein Kinase C (PKC).
• Lithium's Mechanism: A key mechanism of action for lithium is the inhibition of the inositol phosphate signaling pathway. By inhibiting enzymes that recycle inositol, lithium dampens the signaling of Gq-coupled receptors (like 5-HT2A and M1), which may contribute to its mood-stabilizing effects.

3.4. Nuclear Receptors

This is the third major class of receptors. They are located intracellularly and function as transcription factors to directly alter gene expression.

• Mechanism: Lipophilic (fat-soluble) ligands like corticosteroids (e.g., cortisol) and thyroid hormones can easily cross the cell membrane. They bind to their corresponding receptors in the cytoplasm or nucleus. This binding causes the receptor-ligand complex to move to the nucleus, bind to DNA, and change the rate at which specific genes are transcribed into proteins.

Part 4: Important Neurotransmitter & Neuropeptide Systems

4.1. Dopamine (DA)

Dopamine is a monoamine neurotransmitter that plays a critical role in motivation, reward, motor control, and executive function. Its dysregulation is implicated in psychosis, addiction, Parkinson's disease, and ADHD.

4.1.1. Synthesis, Metabolism, and Important Enzymes

Dopamine is a catecholamine, synthesized from the amino acid L-tyrosine.

• Synthesis Pathway:
  1. L-Tyrosine → L-DOPA: The precursor, L-tyrosine, is hydroxylated (an -OH group is added) to form L-DOPA. This is the rate-limiting step for all catecholamine synthesis and is catalyzed by the enzyme Tyrosine Hydroxylase.
  2. L-DOPA → Dopamine: L-DOPA is then rapidly decarboxylated (a -COOH group is removed) to form dopamine. This is catalyzed by aromatic L-amino acid decarboxylase (also known as DOPA decarboxylase).
• Degradation Pathway: Dopamine's action is terminated by reuptake into the presynaptic neuron via the Dopamine Transporter (DAT). Once inside the neuron, it is either repackaged into vesicles or degraded by two key enzymes:
  1. Monoamine Oxidase B (MAO-B): This enzyme is located on the outer membrane of mitochondria within the presynaptic terminal. It is the primary enzyme responsible for degrading dopamine inside the neuron.
  2. Catechol-O-Methyl Transferase (COMT): This enzyme is located primarily in the synaptic cleft and postsynaptic neuron. It is responsible for degrading dopamine that has not been taken back up into the presynaptic neuron.

4.1.2. Receptors

All dopamine receptors are metabotropic G-protein coupled receptors (GPCRs), meaning they have a 7-transmembrane structure. They are divided into two main families with opposing actions on the second messenger cAMP.

• D1-like Family (D₁ and D₅):
  • Coupled to a Gs (stimulatory) protein.
  • Action: Increases the activity of the enzyme adenylyl cyclase, leading to an increase in the second messenger cAMP.
  • Generally considered excitatory.
• D2-like Family (D₂, D₃, and D₄):
  • Coupled to a Gi (inhibitory) protein.
  • Action: Inhibits the activity of adenylyl cyclase, leading to a decrease in the second messenger cAMP.
  • Generally considered inhibitory. This family is the primary target for all antipsychotic medications.
  • Amisulpride is an antipsychotic noted for its high selectivity for D₂/D₃ receptors with minimal activity at other receptors.
• Receptor Abundance: There is some ambiguity in literature regarding which receptor is most abundant. D₁ receptors are the most widely distributed throughout the brain. However, D₂ receptors are highly concentrated in key areas like the striatum and are the most clinically relevant target for antipsychotics. For exam purposes, be aware of this nuance, but D₂ is the most important receptor in psychopharmacology.

4.1.3. The Concept of Partial Agonism

A partial agonist is a drug that binds to and activates a receptor, but has only partial efficacy relative to a full agonist. In the dopamine system, this creates a unique "stabilizing" effect.

• Mechanism:
  • In a high-dopamine environment (e.g., mesolimbic pathway in psychosis), a partial agonist competes with the full agonist (dopamine) for the receptor. Because it produces a weaker signal, the net effect is a reduction in overall dopamine transmission (acting like an antagonist).
  • In a low-dopamine environment (e.g., mesocortical pathway), the partial agonist provides a baseline level of stimulation that is greater than zero, thus increasing net dopamine transmission (acting like an agonist).
• Important Examples: Aripiprazole, Brexpiprazole, and Cariprazine are the classic D₂ partial agonists. Cariprazine is noted to have a preference for D₃ over D₂ receptors.
• Clinical Application: This stabilizing effect is highly useful.
  • Hyperprolactinemia: Full D₂ antagonists (like risperidone) block dopamine in the tuberoinfundibular pathway, causing prolactin levels to rise. A partial agonist like aripiprazole provides enough dopaminergic tone to keep prolactin levels normal, making it an effective strategy to counter this side effect.
  • Schizophrenia & Depression: Aripiprazole is approved for both schizophrenia (reducing mesolimbic hyperactivity) and as an adjunctive treatment for depression (potentially boosting mesocortical/prefrontal dopamine).

4.1.4. Neurochemical Hypotheses of Schizophrenia

The original dopamine hypothesis proposed that psychosis was due to excessive dopamine. This has been refined to a more nuanced model.

• Mesolimbic Pathway: Hyperactivity (too much dopamine) in this pathway is thought to underlie the positive symptoms of schizophrenia (e.g., hallucinations, delusions).
• Mesocortical Pathway: Hypoactivity (too little dopamine) in this pathway, particularly projecting to the dorsolateral prefrontal cortex (DLPFC), is thought to underlie the negative and cognitive symptoms (e.g., anhedonia, executive dysfunction).

4.2. Noradrenaline (NA / Norepinephrine, NE)

Noradrenaline is a monoamine neurotransmitter and hormone belonging to the catecholamine family. It is the primary neurotransmitter of the sympathetic nervous system and plays a crucial role in the central nervous system in regulating arousal, vigilance, attention, mood, and the "fight-or-flight" stress response.

4.2.1. Synthesis and Metabolism

The synthesis of noradrenaline is a direct continuation of the dopamine pathway, occurring within noradrenergic neurons.

• Synthesis Pathway:
  1. L-Tyrosine → L-DOPA → Dopamine (as described previously).
  2. Dopamine → Noradrenaline: Inside synaptic vesicles, the enzyme dopamine β-hydroxylase adds a hydroxyl (-OH) group to dopamine, converting it into noradrenaline.
• Degradation Pathway: Like dopamine, noradrenaline's action is terminated by reuptake via the Noradrenaline Transporter (NET). Once inside the presynaptic neuron, it is degraded by:
  1. Monoamine Oxidase A (MAO-A): While MAO-B preferentially metabolizes dopamine, MAO-A shows a higher affinity for noradrenaline and serotonin.
  2. Catechol-O-Methyl Transferase (COMT): Acts on noradrenaline in the synaptic cleft.

4.2.2. Receptors

All noradrenergic receptors (adrenoceptors) are metabotropic G-protein coupled receptors (GPCRs). They are divided into two main classes, alpha (α) and beta (β), each with important subtypes.

• Alpha (α) Receptors:
  • α₁ Receptors: Gq-protein coupled (excitatory). They are primarily postsynaptic and mediate many of the excitatory and vasoconstrictive effects. Blockade by drugs like prazosin or many antipsychotics (e.g., clozapine, quetiapine) causes vasodilation, leading to the side effect of orthostatic hypotension.
  • α₂ Receptors: Gi-protein coupled (inhibitory). They are primarily presynaptic autoreceptors. When noradrenaline binds, it inhibits its own further release.
    • Agonists (e.g., clonidine, guanfacine) stimulate these receptors, reducing sympathetic outflow. This is their mechanism for treating hypertension and ADHD.
    • Antagonists (e.g., mirtazapine) block this negative feedback brake, increasing the release of noradrenaline and serotonin.
• Beta (β) Receptors (β₁, β₂, β₃):
  • Gs-protein coupled (stimulatory).
  • They are postsynaptic, mediating many of the metabolic and cardiac effects.
  • Beta-blockers (e.g., propranolol) are antagonists at these receptors, reducing the peripheral physical symptoms of anxiety (e.g., tachycardia, tremor).

4.2.3. Pharmacological Modulation

The noradrenergic system is a key target for many antidepressants and ADHD medications.

• Reuptake Inhibition:
  • SNRIs (Serotonin-Noradrenaline Reuptake Inhibitors): Drugs like venlafaxine and duloxetine block both SERT and the Noradrenaline Transporter (NET), increasing synaptic levels of both neurotransmitters. The noradrenergic effect of venlafaxine is particularly prominent at higher doses and is responsible for its dose-dependent risk of hypertension.
  • NRIs (Noradrenaline Reuptake Inhibitors): Drugs like reboxetine and atomoxetine are selective for NET. Atomoxetine's efficacy in ADHD is thought to stem from its ability to increase noradrenaline (and indirectly, dopamine) levels in the prefrontal cortex.
  • TCAs (Tricyclic Antidepressants): Most TCAs (e.g., imipramine, amitriptyline) are potent inhibitors of both serotonin and noradrenaline reuptake.
• Receptor Modulation:
  • Mirtazapine: As mentioned, its primary antidepressant mechanism is α₂-autoreceptor antagonism, which disinhibits and increases the release of both noradrenaline and serotonin.

4.3. Serotonin (5-Hydroxytryptamine, 5-HT)

Serotonin is a monoamine neurotransmitter that plays a vast and multifaceted role in regulating mood, anxiety, sleep, appetite, cognition, and perception. Its extensive receptor family allows for highly diverse and sometimes opposing effects, making it a primary target for a wide range of psychotropic medications.

4.3.1. Synthesis and Metabolism

• Synthesis Pathway:
  1. L-Tryptophan → 5-HTP: The synthesis begins with the essential amino acid L-tryptophan, which must be obtained from the diet. The enzyme tryptophan hydroxylase converts it to 5-HTP. The availability of tryptophan is the primary rate-limiting step for serotonin synthesis.
  2. 5-HTP → Serotonin (5-HT): 5-HTP is then converted to serotonin by the enzyme aromatic L-amino acid decarboxylase.
• Degradation Pathway: Serotonin's action is terminated by reuptake into the presynaptic neuron via the Serotonin Transporter (SERT). Once inside the neuron, it is degraded primarily by Monoamine Oxidase A (MAO-A).

4.3.2. Receptor Subtypes and Functions

The serotonin system is incredibly complex, with at least 14 distinct receptor subtypes. All are metabotropic (GPCRs) except for the 5-HT3 receptor. Understanding the function of key subtypes is crucial for the MRCPsych exam.

• 5-HT1A Receptors: Gi-coupled (inhibitory). Stimulation is associated with antidepressant and anxiolytic effects. Presynaptic 5-HT1A autoreceptors act as a brake on serotonin release. Buspirone is a 5-HT1A partial agonist.
• 5-HT2A Receptors: Gq-coupled (excitatory). Stimulation is associated with anxiety, insomnia, sexual dysfunction, and the hallucinogenic effects of drugs like LSD. Antagonism is a key mechanism of atypical antipsychotics. ECT is known to cause a reduction (downregulation) in 5-HT2 receptor density.
• 5-HT2C Receptors: Gq-coupled (excitatory). Antagonism is strongly linked to the weight gain seen with antipsychotics like olanzapine and antidepressants like mirtazapine.
• 5-HT3 Receptors: The only ionotropic serotonin receptor. Stimulation is associated with nausea and vomiting. Antagonism is the mechanism of anti-emetic drugs like ondansetron.

4.3.3. Pharmacological Modulation

The serotonin system is the most common target for antidepressant medications.

• Reuptake Inhibition (SERT Blockade):
  • SSRIs: e.g., fluoxetine, sertraline, citalopram. These drugs block SERT, increasing the amount and duration of serotonin in the synaptic cleft.
  • Sertraline is unique among SSRIs for also having a moderate inhibitory effect on the Dopamine Transporter (DAT).
  • Fluoxetine is notable for its 5-HT2C antagonist properties.
• Multi-modal Agents:
  • Vortioxetine: Has a complex mechanism, acting as a SERT inhibitor, 5-HT1A agonist, and an antagonist at 5-HT3, 5-HT7, and 5-HT1D receptors.
  • Trazodone (SARI): Combines weak SERT inhibition with potent 5-HT2A antagonism.

4.4. Acetylcholine (ACh)

Acetylcholine is a small-molecule neurotransmitter that plays a vital role in both the central and peripheral nervous systems. In the CNS, it is crucial for learning, memory, attention, and arousal. Its depletion is a key feature of Alzheimer's disease.

4.4.1. Synthesis and Metabolism

The synthesis and degradation of acetylcholine are rapid and highly efficient.

• Synthesis:
  • Precursors: Choline and Acetyl Coenzyme A (Acetyl-CoA). Choline transport into the neuron is the rate-limiting step.
  • Enzyme: Choline Acetyltransferase (ChAT) catalyzes the reaction.
• Degradation:
  • Unlike monoamines, ACh action is not terminated by reuptake.
  • Instead, it is rapidly broken down in the synaptic cleft by the enzyme Acetylcholinesterase (AChE), a diffusion-limited enzyme.
  • The resulting choline is transported back into the presynaptic neuron for recycling.

4.4.2. Receptors

Acetylcholine acts on two major families of receptors.

• Nicotinic Receptors (nAChRs):
  • Type: Ionotropic (ligand-gated cation channels).
  • Mechanism: Cause rapid depolarization (excitation).
  • Pharmacology: Bupropion is a nicotinic receptor antagonist, contributing to its efficacy as a smoking cessation aid.
• Muscarinic Receptors (mAChRs):
  • Type: Metabotropic (GPCRs).
  • Pharmacology:
    • Antagonists (Anticholinergics): Many TCAs (e.g., amitriptyline) and antipsychotics (e.g., clozapine) block muscarinic receptors, causing side effects like dry mouth, blurred vision, constipation, and cognitive impairment.
    • M4 Agonism: The hypersalivation seen with clozapine is a paradoxical effect mediated by its agonist activity at the M4 receptor subtype.

4.4.3. Clinical Relevance: The Cholinergic Hypothesis of Alzheimer's Disease

• The Hypothesis: A core pathological feature of Alzheimer's disease is the severe loss of cholinergic neurons originating in the basal forebrain (e.g., Nucleus Basalis of Meynert). This cholinergic deficit is strongly correlated with the decline in memory and attention.
• Therapeutic Strategy: The primary treatment is to boost cholinergic function by inhibiting the enzyme that breaks down acetylcholine.
• Acetylcholinesterase Inhibitors (AChEIs): Drugs like donepezil, rivastigmine, and galantamine are reversible inhibitors of AChE, increasing the amount of acetylcholine in the synaptic cleft.

4.5. Gamma-Aminobutyric Acid (GABA)

GABA is the principal inhibitory neurotransmitter in the mature central nervous system. Its primary function is to reduce neuronal excitability. It plays a crucial role in anxiety, sedation, sleep, and seizure control and is the target of benzodiazepines, Z-drugs, and barbiturates.

4.5.1. Synthesis and Metabolism

GABA is synthesized directly from the brain's main excitatory neurotransmitter, glutamate, creating a delicate balance between excitation and inhibition.

• Synthesis:
  • Precursor: Glutamate.
  • Enzyme: Glutamate Decarboxylase (GAD) catalyzes the conversion of glutamate to GABA.
• Degradation: GABA is metabolized by the enzyme GABA transaminase.

4.5.2. Receptors

GABA acts on two major classes of receptors with distinct structures and mechanisms.

• GABA-A Receptors:
  • Type: Ionotropic (ligand-gated chloride channel).
  • Mechanism: When GABA binds, the channel opens, allowing chloride ions (Cl⁻) to flow into the neuron, causing rapid inhibition.
  • Allosteric Modulation:
    • Benzodiazepines (e.g., Diazepam) are positive allosteric modulators that increase the frequency of channel opening.
    • Z-drugs (e.g., Zolpidem, Zopiclone) are selective for receptors containing the α1 subunit, which mediates sedation.
    • Barbiturates bind to a different site and increase the duration of channel opening.
• GABA-B Receptors:
  • Type: Metabotropic (Gi-coupled GPCR).
  • Mechanism: Produces slower, more prolonged inhibition.
  • Pharmacology: Gamma-hydroxybutyrate (GHB) is an agonist at GABA-B receptors.

4.5.3. Clinical and Pharmacological Relevance

• Flumazenil: This drug is a competitive antagonist at the benzodiazepine binding site on the GABA-A receptor. It is used as an antidote to reverse overdose with benzodiazepines and Z-drugs.
• GABAergic Neurons: Medium spiny neurons are the principal output neurons of the striatum (e.g., caudate nucleus) and are primarily GABAergic.
• Important Distinction (Gabapentinoids): Drugs like Pregabalin and Gabapentin, despite their names, do not act directly on GABA receptors. Their mechanism is binding to the α2δ subunit of voltage-gated calcium channels, reducing the release of excitatory neurotransmitters like glutamate.

4.6. Glutamate

Glutamate is the most abundant neurotransmitter in the brain and the principal fast excitatory neurotransmitter. It is critically involved in nearly all aspects of normal brain function, including learning, memory, and synaptic plasticity. However, excessive glutamatergic activity can be neurotoxic.

4.6.1. Synthesis and the Glutamate-Glutamine Cycle

Glutamate does not readily cross the blood-brain barrier and must be synthesized within the brain. The glutamate-glutamine cycle is the primary mechanism for replenishing neuronal glutamate stores while preventing its toxic accumulation in the synapse.

• Synthesis: Glutamate can be synthesized from glucose via the Krebs cycle. A key immediate step is the conversion of glutamine to glutamate by the enzyme glutaminase within the presynaptic neuron.
• The Cycle:
  1. Glutamate is released from presynaptic neurons.
  2. Its action is terminated by rapid uptake into surrounding astrocytes.
  3. Inside the astrocyte, the enzyme glutamine synthetase converts glutamate into glutamine.
  4. Glutamine is then transported back to the neuron to be converted back into glutamate.

4.6.2. Receptors

Glutamate receptors are divided into ionotropic (fast) and metabotropic (slow) classes.

• Ionotropic Glutamate Receptors:
  • AMPA Receptors: Mediate the vast majority of fast excitatory neurotransmission. They are simple glutamate-gated sodium (Na⁺) channels.
  • NMDA Receptors: Crucial for synaptic plasticity. They are glutamate-gated calcium (Ca²⁺) channels and have several special properties:
    1. Co-agonist Requirement: Require binding of both glutamate and a co-agonist (glycine or D-serine).
    2. Voltage-Dependence: At rest, the channel is blocked by a magnesium ion (Mg²⁺). The channel only opens when the neuron is already partially depolarized, which repels the Mg²⁺ ion.

4.7. Endocannabinoids

The endocannabinoid system is a unique neuromodulatory system that plays a crucial role in regulating neurotransmitter release, synaptic plasticity, appetite, pain, mood, and memory. Unlike classical neurotransmitters, endocannabinoids are synthesized "on-demand" and act as retrograde messengers.

4.7.1. Important Ligands and Receptors

• Endogenous Ligands (Endocannabinoids): These are lipid-based signaling molecules. The two most well-studied are:
  1. Anandamide (from the Sanskrit word for "bliss")
  2. 2-Arachidonoylglycerol (2-AG)
• Exogenous Ligands: The primary psychoactive component of cannabis, Δ⁹-tetrahydrocannabinol (THC), is an exogenous agonist.
• Receptors: Both are metabotropic GPCRs.
  1. CB1 Receptors: One of the most abundant GPCRs in the brain, highly concentrated on presynaptic terminals. When activated, they inhibit the release of neurotransmitters from that terminal. They mediate the main psychoactive effects of cannabis.
  2. CB2 Receptors: Found primarily outside the CNS on cells of the immune system and play a role in modulating inflammation.

Part 5: Principles of Psychopharmacology

This section covers pharmacokinetics (what the body does to a drug) and pharmacodynamics (what a drug does to the body), focusing on concepts directly relevant to psychiatric practice.

5.1. Pharmacokinetics

Pharmacokinetics describes the journey of a drug through the body: Absorption, Distribution, Metabolism, and Excretion (ADME).

5.1.1. Absorption & Bioavailability

• Bioavailability: The fraction of an administered dose that reaches the systemic circulation unchanged.
• Effect of Food:
  • Increased Absorption: Some lipophilic (fat-soluble) drugs require fat for optimal absorption. Their bioavailability increases significantly when taken with a meal.
    • Ziprasidone: Bioavailability can double with a meal of ≥500 kcal.
    • Lurasidone: Bioavailability increases 2-3 fold with a meal of ≥350 kcal.
• Area Under the Curve (AUC): The primary measure of total drug exposure over time, representing the total amount of drug the body is exposed to. It is a key indicator of bioavailability.

5.1.2. Distribution

• Volume of Distribution (Vd): A theoretical volume representing how extensively a drug is distributed. Lipophilic drugs have a large Vd as they accumulate in fatty tissues.
• Protein Binding: Many drugs bind to plasma proteins like albumin. Only the unbound (free) fraction is pharmacologically active. Fluoxetine is notable for its very high protein binding (~95%).
• Pharmacokinetics in the Elderly: Older adults have more body fat. This increases the volume of distribution for lipophilic drugs, prolonging their half-life and increasing the risk of accumulation.
• P-glycoprotein (P-gp): An efflux pump at the blood-brain barrier that actively pumps many drugs (including some psychotropics) out of the brain.

5.1.3. Metabolism

• Metabolism: Chemical conversion of a drug, primarily in the liver by Cytochrome P450 (CYP) enzymes.
• Prodrugs vs. Active Metabolites:
  • Prodrug: An inactive substance metabolized into an active drug (e.g., lisdexamfetamine → dexamfetamine).
  • Active Metabolite: An active drug metabolized into another active substance (e.g., imipramine → desipramine).
• Enzyme Induction: Smoking is a potent inducer of CYP1A2, which metabolizes drugs like clozapine and olanzapine, leading to lower drug levels.
• Enzyme Inhibition: Fluoxetine is a potent inhibitor of CYP2D6, which can lead to dangerously high levels of other drugs metabolized by this enzyme (e.g., TCAs, risperidone).

5.1.4. Elimination & Half-Life

• Kinetics:
  • First-Order Kinetics: Most drugs. A constant fraction (%) is eliminated per unit of time.
  • Zero-Order (Non-Linear) Kinetics: A constant amount is eliminated per unit of time. This occurs when metabolic enzymes become saturated. Drugs like phenytoin, ethanol, and at high doses, fluoxetine, follow this pattern.
• Half-Life (t½): The time for plasma concentration to decrease by 50%. It takes approximately 5 half-lives for a drug to be effectively eliminated (>96% cleared).
• Physiological Factors:
  • Pregnancy: The glomerular filtration rate (GFR) increases significantly, which can increase the renal clearance of drugs like lithium.

5.2. Pharmacodynamics & Drug Interactions

Pharmacodynamics describes the effects of a drug on the body, including its mechanism of action at the receptor level and the resulting physiological changes.

5.2.1. Receptor Occupancy Theory

The effects of a drug are generally proportional to the number of receptors it occupies. This is particularly relevant for antipsychotics and the dopamine D₂ receptor.

• Therapeutic Window: For antipsychotic efficacy, it is generally accepted that 60-75% of striatal D₂ receptors need to be occupied (blocked).
• Threshold for Extrapyramidal Symptoms (EPS): When D₂ receptor occupancy exceeds a certain threshold, the risk of motor side effects (EPS) increases dramatically. This threshold is approximately 80%.

5.2.2. Receptor Affinity and Side Effects

Many psychotropic drugs are "dirty drugs," meaning they bind to multiple different receptor types. Their side effect profile is often a direct result of their affinity for these "off-target" receptors.

• H1 (Histamine) Receptor Antagonism: Causes sedation and weight gain. Potent antagonists include mirtazapine, clozapine, and olanzapine.
• α1 (Alpha-1 Adrenergic) Receptor Antagonism: Causes orthostatic hypotension and dizziness. Potent antagonists include clozapine, quetiapine, and risperidone. Aripiprazole has minimal α1 affinity.
• M1 (Muscarinic) Receptor Antagonism (Anticholinergic Effects): Causes dry mouth, blurred vision, constipation, urinary retention, and cognitive impairment. Potent antagonists include TCAs (especially amitriptyline) and clozapine.

5.2.3. Drug Interactions

• MAOI Interactions:
  • Interaction with Sympathomimetics (e.g., pseudoephedrine) leads to a massive surge of noradrenaline, causing a hypertensive crisis.
• Lithium Interactions:
  • Interaction with ACE Inhibitors & NSAIDs can reduce the kidney's ability to clear lithium, increasing the risk of lithium toxicity.

5.3. Neurochemical Basis of Iatrogenic Syndromes

This section covers distinct clinical syndromes caused by the neurochemical effects of psychotropic medications. Understanding the underlying pathophysiology is essential for diagnosis, management, and answering safety-related questions on the exam.

5.3.1. Serotonin Syndrome

• Definition: A potentially life-threatening condition caused by excessive serotonergic activity in the central and peripheral nervous systems.
• Neurochemical Basis: The core mechanism is the overstimulation of serotonin receptors, particularly the postsynaptic 5-HT2A and possibly 5-HT1A receptors. This is often caused by combining multiple drugs that increase serotonin levels (e.g., an SSRI with an MAOI or tramadol).
• The Clinical Triad:
  1. Cognitive/Mental Status Changes: Agitation, confusion, restlessness, delirium.
  2. Autonomic Instability: Hyperthermia, diaphoresis (sweating), tachycardia, hypertension.
  3. Neuromuscular Hyperactivity: This is a key diagnostic feature. It includes hyperreflexia, tremor, myoclonus, and most characteristically, inducible or spontaneous clonus (especially at the ankles).
• Important Distinction from NMS: Serotonin syndrome is characterized by hyper-reflexia and clonus, whereas Neuroleptic Malignant Syndrome (NMS) presents with "lead-pipe" rigidity and hypo-reflexia.

5.3.2. Neuroleptic Malignant Syndrome (NMS)

• Definition: A rare but life-threatening idiosyncratic reaction to dopamine-blocking agents.
• Neurochemical Basis: The central mechanism is a sudden and profound blockade of D₂ receptors in multiple pathways.
  • Nigrostriatal Pathway: Blockade here causes the extreme "lead-pipe" muscle rigidity.
  • Hypothalamus: Blockade here disrupts thermoregulation, leading to hyperthermia (fever).
• The Clinical Tetrad:
  1. Mental Status Change (Delirium, stupor)
  2. Extreme Muscle Rigidity ("Lead-pipe")
  3. Hyperthermia (Fever)
  4. Autonomic Instability (Tachycardia, labile BP)

5.3.3. Acute Dystonia

• Definition: An acute, drug-induced movement disorder characterized by painful, sustained, involuntary muscle contractions, typically occurring within hours to days of starting a D₂ blocking agent.
• Neurochemical Basis: Believed to be caused by an acute disruption of the dopamine-acetylcholine balance in the nigrostriatal pathway. The sudden D₂ blockade leads to a state of relative cholinergic overactivity.
• Classic Presentations: Oculogyric crisis (forced upward deviation of the eyes), torticollis (neck twisting), opisthotonos (arching of the back).

5.3.4. Drug-Induced Parkinsonism

• Definition: A sub-acute extrapyramidal syndrome that mimics Parkinson's disease, developing weeks to months after starting a D₂ blocking agent.
• Neurochemical Basis: Caused by the blockade of D₂ receptors in the nigrostriatal pathway, creating a functional state of dopamine deficiency.
• Clinical Features: Bradykinesia (slowness), tremor (often "pill-rolling"), and rigidity. Axial rigidity (stiffness of the neck and trunk) is a common presentation.

5.3.5. Tardive Dyskinesia (TD)

• Definition: A potentially irreversible, late-onset movement disorder characterized by involuntary, repetitive movements after long-term exposure to dopamine-blocking agents.
• Neurochemical Basis: The leading hypothesis is the development of D₂ receptor supersensitivity in the basal ganglia. Chronic blockade causes postsynaptic neurons to compensate by increasing the number and sensitivity of their D₂ receptors, making the pathway hypersensitive to any available endogenous dopamine.
• Clinical Features: Classic presentation involves oro-bucco-lingual movements: repetitive lip-smacking, chewing motions, and tongue protrusions.

5.3.6. Syndrome of Inappropriate ADH (SIADH)

• Definition: A condition of excessive release of antidiuretic hormone (ADH), leading to water retention and subsequent dilutional hyponatremia (low serum sodium).
• Neurochemical Basis: Believed to involve inappropriate stimulation of ADH release from the hypothalamus. Serotonergic pathways may play a modulatory role.
• Causative Agents: Most commonly associated with SSRIs (especially in the elderly), but also carbamazepine and TCAs.
• Clinical & Lab Features: Confusion, lethargy. Labs show low serum sodium, low serum osmolality, euvolemia, and an inappropriately high urine osmolality.

Part 6: Neurochemistry of Pathological States

This section focuses on the molecular basis of specific diseases. A central theme is proteinopathy—diseases caused by the misfolding and aggregation of proteins into toxic structures.

6.1. The Proteinopathies: Misfolded Proteins in Neurodegeneration

6.1.1. α-Synucleinopathies

• Protein: The core pathology involves the misfolding and aggregation of the protein alpha-synuclein (encoded by the SNCA gene).
• Pathological Inclusion: Aggregates form characteristic intracellular deposits.
  • In neurons, they are called Lewy bodies.
  • In glial cells, they are called glial cytoplasmic inclusions.
• Associated Diseases:
  • Parkinson's Disease: Loss of dopaminergic neurons in the substantia nigra and presence of Lewy bodies.
  • Dementia with Lewy Bodies (LBD): Widespread cortical Lewy bodies.
  • Multiple System Atrophy (MSA): Glial cytoplasmic inclusions.

6.1.2. Tauopathies

• Protein: Involves the hyperphosphorylation and aggregation of the tau protein (encoded by the MAPT gene), which normally stabilizes the neuron's internal skeleton (microtubules).
• Pathological Inclusions:
  • Neurofibrillary Tangles (NFTs): Intracellular tangles of hyperphosphorylated tau, a key hallmark of Alzheimer's disease.
  • Pick Bodies: Round, silver-staining intracellular inclusions containing tau, characteristic of Pick's disease (a subtype of Frontotemporal Dementia).
• Associated Diseases:
  • Alzheimer's Disease (considered a secondary tauopathy)
  • Frontotemporal Dementia (FTD-tau)
  • Progressive Supranuclear Palsy (PSP) and Corticobasal Degeneration.

6.1.3. Amyloid-beta Pathology

• Protein: Aggregation of the amyloid-beta (Aβ) peptide.
• Precursor & Enzymes: Aβ is cleaved from a larger protein, Amyloid Precursor Protein (APP).
  • The "bad" pathway involves sequential cleavage by β-secretase and then γ-secretase, producing the toxic Aβ peptide.
• Pathological Inclusion: Aβ peptides aggregate to form extracellular senile plaques, the primary hallmark of Alzheimer's disease.

6.1.4. Prionopathies (Transmissible Spongiform Encephalopathies)

• Protein: Misfolding of the Prion Protein (PrP). The normal form is PrPᶜ, the infectious form is PrPˢᶜ.
• Mechanism: The pathogenic PrPˢᶜ acts as a template, forcing normal PrPᶜ proteins to misfold in a chain reaction, leading to aggregation and widespread neuronal death ("spongy" appearance).
• Associated Diseases: Creutzfeldt-Jakob Disease (CJD), Variant CJD, Kuru, and Fatal Familial Insomnia.

Part 7: Neuroinflammation & Molecular Genetics

This section explores how inflammation and genetic factors contribute to the neurochemical basis of psychiatric illness.

7.1. Role of Cytokines in Psychiatry

Cytokines are small proteins that act as signaling molecules for the immune system. A chronic, low-grade pro-inflammatory state is implicated in the pathophysiology of mood and anxiety disorders.

• Pro-inflammatory Cytokines:
  • Interleukin-6 (IL-6): This is the most robustly and consistently elevated pro-inflammatory cytokine found in patients with major depression and Generalized Anxiety Disorder (GAD).
  • Others implicated include Tumor Necrosis Factor-alpha (TNF-α) and Interleukin-1β (IL-1β).
• HIV & Neuroinflammation: In HIV-associated neurocognitive disorder (HAND), a state of chronic neuroinflammation often persists, characterized by elevated CD8⁺ T-cells in the CNS.

7.2. Genetic Polymorphisms of Neurochemical Importance

Psychiatric disorders are polygenic, meaning risk is conferred by the combined small effects of many common genetic variations (polymorphisms).

• Apolipoprotein E (APOE) ε4 Allele:
  • Relevance: The ε4 allele of the APOE gene is the single strongest genetic risk factor for late-onset Alzheimer's disease.
  • Homozygous (two copies) confers an approximately 10-30 fold increased risk.
• Ion Channelopathies in Psychiatry:
  • Voltage-gated Calcium Channels: The CACNA1C gene is one of the most robustly identified risk genes for bipolar disorder.
  • Potassium Channels: The KCNN3 gene has been identified as a susceptibility gene for schizophrenia.
• Genes related to Synaptic Function:
  • SHANK3: Mutations in this gene are strongly associated with Autism Spectrum Disorder (ASD).

Part 8: Neurochemical Investigation Techniques

This section covers the key methods used to measure and manipulate neurochemical processes in the living brain.

8.1. In Vivo Measurement

These techniques allow for the non-invasive measurement of neurochemical markers in living subjects.

• Magnetic Resonance Spectroscopy (MRS):
  • Application: The only non-invasive technique that can reliably quantify the in vivo concentration of certain brain metabolites, including Glutamate, GABA, and N-acetylaspartate (NAA) - a marker of neuronal viability.
• Positron Emission Tomography (PET):
  • Principle: Uses radiotracers labeled with positron-emitting isotopes (e.g., Carbon-11 [¹¹C]).
  • Applications: Measuring receptor occupancy (e.g., using ¹¹C-raclopride for D₂ receptors) and visualizing pathological proteins (e.g., using ¹¹C-PiB for beta-amyloid plaques).
• Single-Photon Emission Computed Tomography (SPECT):
  • Application: Primarily used for measuring the density of neurotransmitter transporters. The Dopamine Transporter (DAT) Scan is the most common clinical application, used to differentiate neurodegenerative parkinsonian syndromes from other causes.

8.2. Advanced Research Concepts & Tools

These are cutting-edge techniques used in neuroscience research to manipulate and study neural circuits with high precision.

• Optogenetics:
  • Principle: Combines genetics and light to control specific neurons.
  • Important Opsins (light-sensitive channels):
    • Channelrhodopsin (ChR2): Opens in response to blue light, causing neuronal activation.
    • Halorhodopsin: A chloride pump activated by yellow light, causing neuronal inhibition.
• Chemogenetics (DREADDs):
  • Principle: Uses a designer drug to control neuronal activity.
  • Mechanism: A synthetic receptor (DREADD) is introduced into neurons. This receptor is activated exclusively by an inert drug, most commonly Clozapine-N-oxide (CNO).
• Intermittent Theta-Burst Stimulation (iTBS):
  • Principle: A patterned form of rTMS that induces long-term potentiation (LTP)-like synaptic plasticity.
  • Neurochemical Effect: Has been shown to modulate the balance of excitation and inhibition, specifically by restoring the GABA/glutamate equilibrium.